H Sinzinger, P Schmid, J O'Grady. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » AdolescentAdultCreatine Kinase/bloodDose-Response Relationship, DrugExerciseFatty Acids, Monounsaturated/adverse effectsFatty Acids, Monounsaturated/therapeutic useFemaleFluvastatinHumansHydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosageHydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effectsHyperlipoproteinemia Type II/complicationsHyperlipoproteinemia Type II/drug therapyIndoles/adverse effectsIndoles/therapeutic useLovastatin/adverse effectsLovastatin/therapeutic useMaleMiddle AgedMuscle Cramp/chemically inducedMuscle, Skeletal/drug effectsMuscle, Skeletal/metabolismPain/chemically inducedPain/metabolismPravastatin/adverse effectsPravastatin/therapeutic usePrognosisRisk AssessmentSimvastatin/adverse effectsSimvastatin/therapeutic useSports
Substances: See more » Fatty Acids, MonounsaturatedHydroxymethylglutaryl-CoA Reductase InhibitorsIndolesFluvastatinLovastatinSimvastatinCreatine KinasePravastatin
Year: 1999 PMID: 10217378 DOI: 10.1016/s0021-9150(98)00310-4
Source DB: PubMed Journal: Atherosclerosis ISSN: 0021-9150 Impact factor: 5.162